Aimed at streamlining its post-Celgene-merger pipeline, Bristol Myers Squibb (BMY +1.0%) has terminated the license agreement and returned global rights to JTX-8064 to Jounce Therapeutics (JNCE +3.0%).
Jounce and Celgene inked their deal in July 2019 under which the former received a nonrefundable upfront payment of $50M.
JTX-8064 is a monoclonal antibody that binds to a protein called LILRB2 receptor. LILRB2 plays
a key role in regulating myeloid cell maturation. Blocking its action
may boost the antitumor effects of T cell immune checkpoint inhibitors.
https://seekingalpha.com/news/3580481-jounce-regains-rights-to-cancer-candidate-from-bristol-myers-squibb
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.